{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T16:05:27Z","timestamp":1791561927675,"version":"4.3.4"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2005,1,10]],"date-time":"2005-01-10T00:00:00Z","timestamp":1105315200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/2.0\/"},{"start":{"date-parts":[[2005,1,10]],"date-time":"2005-01-10T00:00:00Z","timestamp":1105315200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/2.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arthritis Res Ther"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Neutrophils are known to be targets for the biological activity of tumour necrosis factor (TNF)-\u03b1 in the pathogenensis of rheumatoid arthritis (RA). Therefore, these cells may be among the targets of anti-TNF-\u03b1 therapy. In this study we evaluated the effect of therapy with adalimumab (a fully human anti-TNF-\u03b1 mAb; dosage: 40 mg subcutaneously every other week) on certain phenotypic and functional aspects of neutrophils obtained from 10 selected patients with RA and 20 healthy control individuals. Peripheral blood neutrophils were obtained at baseline and during anti-TNF-\u03b1 therapy (2, 6 and 12 weeks after the first administration of adalimumab). All patients had been receiving a stable regimen of hydroxychloroquine, methotrexate and prednisone for at least 3 months before and during the study. Baseline neutrophil chemotaxis was significantly decreased in RA patients when compared with control individuals (<jats:italic>P<\/jats:italic> &lt; 0.001). Two weeks after the first administration of adalimumab, chemotactic activity was completely restored, with no differences noted between patients and control individuals; these normal values were confirmed 6 and 12 weeks after the start of anti-TNF-\u03b1 therapy. Phagocytic activity and CD11b membrane expression on neutrophils were similar between RA patients and control individuals; no modifications were observed during TNF-\u03b1 neutralization. The production of reactive oxygen species, both in resting and PMA (phorbol 12-myristate 13-acetate)-stimulated cells, was significantly higher in RA patients at baseline (<jats:italic>P<\/jats:italic> &lt; 0.05) and was unmodified by anti-TNF-\u03b1 mAb. Finally, we showed that the activation antigen CD69, which was absent on control neutrophils, was significantly expressed on neutrophils from RA patients at baseline (<jats:italic>P<\/jats:italic> &lt; 0.001, versus control individuals); however, the molecule was barely detectable on cells obtained from RA patients during adalimumab therapy. Because CD69 potentially plays a role in the pathogenesis of arthritis, our findings suggest that neutrophils are among the targets of anti-TNF-\u03b1 activity in RA and may provide an insight into a new and interesting mechanism of action of anti-TNF-\u03b1 mAbs in the control of inflammatory arthritis.<\/jats:p>","DOI":"10.1186\/ar1477","type":"journal-article","created":{"date-parts":[[2005,1,12]],"date-time":"2005-01-12T21:29:29Z","timestamp":1105565369000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":35,"title":["Effect of adalimumab on neutrophil function in patients with rheumatoid arthritis"],"prefix":"10.1186","volume":"7","author":[{"given":"Franco","family":"Capsoni","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piercarlo","family":"Sarzi-Puttini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabiola","family":"Atzeni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Minonzio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Bonara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Doria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Carrabba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2005,1,10]]},"reference":[{"key":"1358_CR1","doi-asserted-by":"publisher","first-page":"251","DOI":"10.2165\/00063030-200115040-00005","volume":"15","author":"C Richard-Miceli","year":"2001","unstructured":"Richard-Miceli C, Dougados M: Tumor necrosis factor-a blockers in rheumatoid arthritis. BioDrugs. 2001, 15: 251-259.","journal-title":"BioDrugs"},{"key":"1358_CR2","doi-asserted-by":"publisher","first-page":"2167","DOI":"10.1056\/NEJMra032906","volume":"350","author":"NJ Olsen","year":"2004","unstructured":"Olsen NJ, Stein M: New drugs for rheumatoid arthritis. N Engl J Med. 2004, 350: 2167-2179. 10.1056\/NEJMra032906.","journal-title":"N Engl J Med"},{"key":"1358_CR3","doi-asserted-by":"publisher","first-page":"1594","DOI":"10.1056\/NEJM200011303432202","volume":"343","author":"PE Lipsky","year":"2000","unstructured":"Lipsky PE, van der Heijde DMFM, St Clair EW, Furst DE, Breedveld FC, Kalden JR, Smolen JS, Weisman M, Emery P, Feldmann M, et al: Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med. 2000, 343: 1594-1602. 10.1056\/NEJM200011303432202.","journal-title":"N Engl J Med"},{"key":"1358_CR4","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1056\/NEJM199707173370301","volume":"337","author":"LW Moreland","year":"1997","unstructured":"Moreland LW, Baumgartner SW, Schiff MH, Tindall EA, Fleischmann RM, Weaver AL, Ettlinger RE, Cohen S, Koopman WJ, Mohler K, et al: Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. N Engl J Med. 1997, 337: 141-147. 10.1056\/NEJM199707173370301.","journal-title":"N Engl J Med"},{"key":"1358_CR5","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1002\/art.10697","volume":"48","author":"ME Weinblatt","year":"2003","unstructured":"Weinblatt ME, Keystone EC, Furst DE, Moreland LW, Weisman MH, Birbara CA, Teoh LA, Fischkoff SA, Chartash EK: Adalimumab, a fully human anti-tumor necrosis factor \u03b1 monoclonal antibody for the treatment of rheumatoid arthritis patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum. 2003, 48: 35-45. 10.1002\/art.10697.","journal-title":"Arthritis Rheum"},{"key":"1358_CR6","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/S0140-6736(00)02530-7","volume":"356","author":"PJ Mease","year":"2000","unstructured":"Mease PJ, Goffe BS, Metz J, VanderStoep A, Finck B, Burge DJ: Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet. 2000, 356: 385-390. 10.1016\/S0140-6736(00)02530-7.","journal-title":"Lancet"},{"key":"1358_CR7","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1056\/NEJM200003163421103","volume":"342","author":"DJ Lovell","year":"2000","unstructured":"Lovell DJ, Giannini EH, Reiff A, Cawkwell GD, Silverman ED, Nocton JJ, Stein LD, Gedalia A, Ilowite NT, Wallace CA, Whitmore J, et al: Etanercept in children with polyarticular juvenile rheumatoid arthritis. Pediatric Rheumatology Collaborative Study Group. N Engl J Med. 2000, 342: 763-769. 10.1056\/NEJM200003163421103.","journal-title":"N Engl J Med"},{"key":"1358_CR8","doi-asserted-by":"publisher","first-page":"1398","DOI":"10.1056\/NEJM199905063401804","volume":"340","author":"DH Present","year":"1999","unstructured":"Present DH, Rutgeerts P, Targan S, Hanauer SB, Mayer L, van Hogezand RA, Podolsky DK, Sands BE, Braakman T, DeWoody KL, et al: Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med. 1999, 340: 1398-1405. 10.1056\/NEJM199905063401804.","journal-title":"N Engl J Med"},{"key":"1358_CR9","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1016\/S0167-5699(97)01087-6","volume":"18","author":"SW Edwards","year":"1997","unstructured":"Edwards SW, Hallett MB: Seeing the wood for the trees: the forgotten role of neutrophils in rheumatoid arthritis. Immunol Today. 1997, 18: 320-324. 10.1016\/S0167-5699(97)01087-6.","journal-title":"Immunol Today"},{"key":"1358_CR10","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1002\/path.1408","volume":"201","author":"L Kruidenier","year":"2003","unstructured":"Kruidenier L, Kuiper I, van Duijn W, Mieremet-Ooms MAC, van Hogezand RA, Lamers CBHW, Verspaget HV: Imbalanced secondary mucosal antioxidant response in inflammatory bowel disease. J Pathol. 2003, 201: 17-27. 10.1002\/path.1408.","journal-title":"J Pathol"},{"key":"1358_CR11","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1023\/A:1022354212121","volume":"22","author":"D Biasi","year":"1998","unstructured":"Biasi D, Carletto A, Caramaschi P, Bellavite P, Maleknia T, Scambi C, Favalli N, Bambara LM: Neutrophil functions and IL-8 in psoriatic arthritis and in cutaneous psoriasis. Inflammation. 1998, 22: 533-543. 10.1023\/A:1022354212121.","journal-title":"Inflammation"},{"key":"1358_CR12","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1182\/blood.V79.3.745.745","volume":"79","author":"A Khwaja","year":"1992","unstructured":"Khwaja A, Carver JE, Linch DC: Interactions of granulocyte-macrophage colony-stimulating factor (CSF), granulocyte CSF, and tumor necrosis factor \u03b1 in the priming of the neutrophil respiratory burst. Blood. 1992, 79: 745-753.","journal-title":"Blood"},{"key":"1358_CR13","doi-asserted-by":"publisher","first-page":"3013","DOI":"10.1002\/art.11301","volume":"48","author":"T Ellerin","year":"2003","unstructured":"Ellerin T, Rubin RH, Weinblatt ME: Infections and anti-tumor necrosis factor \u03b1 therapy. Arthritis Rheum. 2003, 48: 3013-3022. 10.1002\/art.11301.","journal-title":"Arthritis Rheum"},{"key":"1358_CR14","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1002\/1529-0131(200001)43:1<38::AID-ANR6>3.0.CO;2-L","volume":"43","author":"PC Taylor","year":"2000","unstructured":"Taylor PC, Peters M, Paleolog E, Chapman PT, Elliott M, McCloskey R, Feldmann M, Maini RN: Reduction of chemokine levels and leukocyte traffic to joints by tumor necrosis factor \u03b1 blockade in patients with rheumatoid arthritis. Arthritis Rheum. 2000, 43: 38-47. 10.1002\/1529-0131(200001)43:1<38::AID-ANR6>3.0.CO;2-L.","journal-title":"Arthritis Rheum"},{"key":"1358_CR15","first-page":"232","volume":"30","author":"A Den Broeder","year":"2003","unstructured":"Den Broeder A, Wanten GJA, Oyen WJG, Naber T, van Riel PLCM, Barrera P: Neutrophil migration and production of reactive oxygen species during treatment with a fully human anti-tumor necrosis factor-\u03b1 monoclonal antibody in patients with rheumatoid arthritis. J Rheumatol. 2003, 30: 232-237.","journal-title":"J Rheumatol"},{"key":"1358_CR16","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1006\/clim.2001.5183","volume":"103","author":"LW Moreland","year":"2002","unstructured":"Moreland LW, Bucy RP, Weinblatt ME, Mohler KM, Spencer-Green GT, Chatham WW: Immune function in patients with rheumatoid arthritis treated with etanercept. Clin Immunol. 2002, 103: 13-21. 10.1006\/clim.2001.5183.","journal-title":"Clin Immunol"},{"key":"1358_CR17","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1042\/cs0970323","volume":"97","author":"JM Noble","year":"1999","unstructured":"Noble JM, Ford GA, Thomas TH: Effect of aging on CD11b and CD69 surface expression by vesicular insertion in human polymorphonuclear leukocytes. Clin Sci. 1999, 97: 323-329. 10.1042\/CS19990042.","journal-title":"Clin Sci"},{"key":"1358_CR18","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1002\/art.1780310302","volume":"31","author":"FC Arnett","year":"1988","unstructured":"Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, Healey LA, Kaplan SR, Liang MH, Luthra HS: The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988, 31: 315-324.","journal-title":"Arthritis Rheum"},{"key":"1358_CR19","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1136\/ard.49.11.916","volume":"49","author":"DM van der Heijde","year":"1990","unstructured":"van der Heijde DM, van'tHof MA, van Riel PL, Theunisse LA, Lubberts EW, van Leeuwen MA, van Rijswijk MH, van de Putte LB: Judging disease activity in clinical practice in rheumatoid arthritis: first step in the development of a disease activity score. Ann Rheum Dis. 1990, 49: 916-920.","journal-title":"Ann Rheum Dis"},{"key":"1358_CR20","first-page":"90","volume-title":"Ann Rheum Dis","author":"GR Burmester","year":"2004","unstructured":"Burmester GR, Monteagudo S\u00e0ez I, Malaise M, Canas da Silva J, Webber DG, Kupper H: Efficacy and safety of adalimumab (Humira\u00ae) in European clinical practice: the ReAct trial. Ann Rheum Dis. 2004, 90-"},{"key":"1358_CR21","doi-asserted-by":"publisher","first-page":"77","DOI":"10.3109\/00365516809076979","volume":"21","author":"A Boyum","year":"1968","unstructured":"Boyum A: Isolation of mononuclear cells and granulocytes from human blood. J Lab Clin Invest. 1968, 21: 77-89.","journal-title":"J Lab Clin Invest"},{"key":"1358_CR22","doi-asserted-by":"publisher","first-page":"335","DOI":"10.3109\/10428199109068083","volume":"4","author":"F Capsoni","year":"1991","unstructured":"Capsoni F, Minonzio F, Ongari AM, Soligo D, Luksch R, Mozzana R, Della Volpe A, Lambertenghi Deliliers G: Abnormal neutrophil chemotaxis after successful bone marrow transplantation. Leukemia Lymphoma. 1991, 4: 335-341.","journal-title":"Leukemia Lymphoma"},{"key":"1358_CR23","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/S0008-8749(03)00002-9","volume":"220","author":"F Atzeni","year":"2002","unstructured":"Atzeni F, Schena M, Ongari AM, Carrabba M, Bonara P, Minonzio F, Capsoni F: Induction of CD69 activation molecule on human neutrophils by GM-CSF, IFN-\u03b3 and IFN-\u03b1. Cell Immunol. 2002, 220: 20-29. 10.1016\/S0008-8749(03)00002-9.","journal-title":"Cell Immunol"},{"key":"1358_CR24","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1080\/09629359891333","volume":"7","author":"F Aglas","year":"1998","unstructured":"Aglas F, Hermann J, Egger G: Abnormal directed migration of blood polymorphonuclear leukocytes in rheumatoid arthritis. Potential role in increased susceptibility to bacterial infections. Mediat Inflamm. 1998, 7: 19-23. 10.1080\/09629359891333.","journal-title":"Mediat Inflamm"},{"key":"1358_CR25","first-page":"283","volume":"42","author":"R Nada","year":"1999","unstructured":"Nada R, Datta U, Deodhar SD, Sehgal S: Neutrophil function in rheumatoid arthritis. Indian J Path Microbiol. 1999, 42: 283-289.","journal-title":"Indian J Path Microbiol"},{"key":"1358_CR26","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1002\/jlb.52.6.630","volume":"52","author":"KL Vollmer","year":"1992","unstructured":"Vollmer KL, Alberts JS, Carper HT, Mandell GL: Tumor necrosis factor-alpha decreases neutrophil chemotaxis to N-formyl-1-methionyl-l-leucyl-1-phenylalanine: analysis of single cell movement. J Leukocyte Biol. 1992, 52: 630-636.","journal-title":"J Leukocyte Biol"},{"key":"1358_CR27","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1016\/S0161-5890(99)00110-8","volume":"36","author":"R Binder","year":"1999","unstructured":"Binder R, Kress A, Kan G, Herrmann K, Kirschfink M: Neutrophil priming by cytokines and vitamin D binding protein (Gc-globulin): impact on C5a-mediated chemotaxis, degranulation and respiratory burst. Mol Immunol. 1999, 36: 885-892. 10.1016\/S0161-5890(99)00110-8.","journal-title":"Mol Immunol"},{"key":"1358_CR28","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1111\/j.1600-0765.1994.tb01101.x","volume":"29","author":"S Agarwal","year":"1994","unstructured":"Agarwal S, Suzuki JB, Riccelli AE: Role of cytokines in the modulation of neutrophil chemotaxis in localized juvenile periodontitis. J Periodontal Res. 1994, 29: 127-137.","journal-title":"J Periodontal Res"},{"key":"1358_CR29","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1002\/art.1780390207","volume":"39","author":"PP Youssef","year":"1996","unstructured":"Youssef PP, Cormack J, Evill CA, Peter DT, Roberts-Thomson PJ, Ahern MJ, Smith MD: Neutrophil trafficking into inflamed joints in patients with rheumatoid arthritis and the effects of methylprednisolone. Arthritis Rheum. 1996, 39: 216-225.","journal-title":"Arthritis Rheum"},{"key":"1358_CR30","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1002\/(SICI)1097-4652(199607)168:1<183::AID-JCP22>3.0.CO;2-7","volume":"168","author":"A Okuda","year":"1996","unstructured":"Okuda A, Kubota M, Sawada M, Koishi S, Kataoka A, Bessho R, Usami I, Lin YW, Adachi S, Furusho K: Methotrexate inhibits superoxide production and chemotaxis in neutrophils activated by granulocyte colony-stimulating factor. J Cell Physiol. 1996, 168: 183-187. 10.1002\/(SICI)1097-4652(199607)168:1<183::AID-JCP22>3.0.CO;2-7.","journal-title":"J Cell Physiol"},{"key":"1358_CR31","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1111\/j.1600-0609.1997.tb00967.x","volume":"59","author":"A Okuda","year":"1997","unstructured":"Okuda A, Kubota M, Watanabe K, Sawada M, Koishi S, Kataoka A, Usami I, Lin YW, Furusho K: Inhibition of superoxide production and chemotaxis by methotrexate in neutrophils primed by TNF-\u03b1 or LPS. Eur J Haematol. 1997, 59: 142-147.","journal-title":"Eur J Haematol"},{"key":"1358_CR32","first-page":"S158","volume-title":"Inflamm Res","author":"NJ Goulding","year":"1998","unstructured":"Goulding NJ, Euzger HS, Butt SK, Perretti M: Novel pathways for glucocorticoid effects on neutrophils in chronic inflammation. Inflamm Res. 1998, S158-S165. 10.1007\/s000110050310."},{"key":"1358_CR33","doi-asserted-by":"publisher","first-page":"1488","DOI":"10.1002\/1529-0131(200007)43:7<1488::AID-ANR11>3.0.CO;2-G","volume":"43","author":"MC Kraan","year":"2000","unstructured":"Kraan MC, de Koster BM, Elferink JG, Post WJ, Breedveld FC, Tak PP: Inhibition of neutrophil migration soon after initiation of treatment with leflunomide or methotrexate in patients with rheumatoid arthritis: findings in a prospective, randomized, double-blind clinical trial in fifteen patients. Arthritis Rheum. 2000, 43: 1488-1495. 10.1002\/1529-0131(200007)43:7<1488::AID-ANR11>3.0.CO;2-G.","journal-title":"Arthritis Rheum"},{"key":"1358_CR34","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1002\/art.1780310816","volume":"31","author":"T Saxne","year":"1988","unstructured":"Saxne T, Palladine MAJ, Heinegard D, Talal N, Wollheim FA: Detection of tumor necrosis factor \u03b1 but not tumor necrosis factor \u03b2 in rheumatoid arthritis synovial fluid and serum. Arthritis Rheum. 1988, 31: 1041-1045.","journal-title":"Arthritis Rheum"},{"key":"1358_CR35","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1002\/art.1780390702","volume":"39","author":"PP Tak","year":"1996","unstructured":"Tak PP, Taylor PC, Breedveld FC, Smeets TJ, Daha MR, Kluin PM, Meinders AE, Maini RN: Decrease in cellularity and expression of adhesion molecules by anti-tumor necrosis factor alpha monoclonal antibody treatment in patients with rheumatoid arthritis. Arthritis Rheum. 1996, 39: 1077-1081.","journal-title":"Arthritis Rheum"},{"key":"1358_CR36","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1002\/art.1780390703","volume":"39","author":"EM Paleolog","year":"1996","unstructured":"Paleolog EM, Hunt M, Elliott MJ, Feldmann M, Maini RN, Woody JN: Deactivation of vascular endothelium by monoclonal anti-tumor necrosis factor alpha antibody in rheumatoid arthritis. Arthritis Rheum. 1996, 39: 1082-1091.","journal-title":"Arthritis Rheum"},{"key":"1358_CR37","first-page":"331","volume":"22","author":"F Atzeni","year":"2004","unstructured":"Atzeni F, Del Papa N, Sarzi-Puttini P, Bertolazzi F, Minonzio F, Capsoni F: CD69 expression on neutrophils from patients with rheumatoid arthritis. Clin Exp Rheumatol. 2004, 22: 331-334.","journal-title":"Clin Exp Rheumatol"},{"key":"1358_CR38","first-page":"161","volume":"14","author":"G Benoni","year":"2001","unstructured":"Benoni G, Adami A, Vella A, Arosio E, Ortolani R, Cuzzolin L: CD23 and CD69 expression on human neutrophils of healthy subjects and patients with peripheral arterial occlusive disease. Int J Immunopath Pharmac. 2001, 14: 161-167.","journal-title":"Int J Immunopath Pharmac"},{"key":"1358_CR39","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1172\/JCI115338","volume":"88","author":"A Laffon","year":"1991","unstructured":"Laffon A, Garcia-Vicu\u00f1a R, Humbria A, Postigo AA, Corbi AL, de Landazuri MO, Sanchez-Madrid F: Upregulated expression and function of VLA-4 fibronectin receptors on human activated T cells in rheumatoid arthritis. J Clin Invest. 1991, 88: 546-552.","journal-title":"J Clin Invest"},{"key":"1358_CR40","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1093\/intimm\/dxg102","volume":"15","author":"K Murata","year":"2003","unstructured":"Murata K, Inami M, Hasegawa A, Kubo S, Kimura M, Yamashita M, Hosokawa H, Nagao T, Suzuki K, Hashimoto K, et al: CD69-null mice protected from arthritis induced with anti-type II collagen antibodies. Int Immunol. 2003, 15: 987-992. 10.1093\/intimm\/dxg102.","journal-title":"Int Immunol"},{"key":"1358_CR41","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1097\/01.shk.0000087203.34916.45","volume":"20","author":"TA Moore","year":"2003","unstructured":"Moore TA, Lau HY, Cogen AL, Monteleon CL, Standiford T: Anti-tumor necrosis factor-\u03b1 therapy during murine Klebsiella pneumoniae bacteremia: increased mortality in the absence of liver injury. Shock. 2003, 20: 309-315. 10.1097\/01.shk.0000087203.34916.45.","journal-title":"Shock"}],"container-title":["Arthritis Res Ther"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/ar1477.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/ar1477\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/ar1477.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,8]],"date-time":"2024-10-08T10:23:54Z","timestamp":1728383034000},"score":1,"resource":{"primary":{"URL":"https:\/\/arthritis-research.biomedcentral.com\/articles\/10.1186\/ar1477"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,1,10]]},"references-count":41,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2005,12]]}},"alternative-id":["1358"],"URL":"https:\/\/doi.org\/10.1186\/ar1477","relation":{},"ISSN":["1478-6354"],"issn-type":[{"value":"1478-6354","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,1,10]]},"assertion":[{"value":"3 September 2004","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 October 2004","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 November 2004","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 January 2005","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"R250"}}